The earnings call presented a generally positive outlook with significant progress in clinical trials and market expansion. However, there are areas of concern such as the decreased growth in non-small cell lung cancer prescriptions, reduced gross margin, and a net loss for the quarter.

Company Guidance

During Novocure's second quarter 2025 earnings call, the company provided detailed guidance on several key metrics, showcasing a robust growth trajectory. The company reported net revenues of $159 million, marking a 6% increase from the same quarter last year, driven by 7% year-over-year growth in active patients within their GBM franchise. Novocure highlighted significant milestones, including the receipt of 121 prescriptions for Optune Lua in non-small cell lung cancer, contributing to $2.4 million in net revenues for this indication. The company also reported promising clinical data, such as the PANOVA-3 trial results in pancreatic cancer, where the TTFields therapy, combined with gemcitabine and nab-paclitaxel, demonstrated a median overall survival of 16.2 months for patients, 2 months longer than the control group. In brain metastases from non-small cell lung cancer, the METIS trial showed a 28% risk reduction in intracranial progression. Novocure is actively pursuing regulatory approvals, with expectations to file PMA submissions for pancreatic cancer and brain metastases in the third quarter. The company remains focused on expanding its indications and is preparing for potential launches in 2026, supported by a strong financial position, including a cash and investment balance of $912 million.

PANOVA-3 Trial Success in Pancreatic Cancer

The PANOVA-3 trial demonstrated a median overall survival of 16.2 months for patients using TTFields therapy combined with gemcitabine and nab-paclitaxel, which is 2 months greater than the control arm. This trial also showed significant improvements in pain-free survival.

METIS Trial Positive Results

The METIS trial met its primary endpoint with a statistically significant improvement in time to intracranial progression for patients treated with TTFields therapy. The trial showed a 28% risk reduction with a median time to progression of 15 months compared to 7.5 months for the control group.

Expansion of Optune Lua in Non-Small Cell Lung Cancer

Received 121 prescriptions for Optune Lua in the second quarter with $2.4 million in net revenues. The product is now being used widely with immune checkpoint inhibitors and docetaxel.

11th Consecutive Quarter of Active Patient Growth

The company saw a 7% increase in active patients, with all international markets experiencing double-digit growth.

NovoCure (NVCR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NVCR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	-0.42 / -	-0.28	―	―	―
Jul 24, 2025	2025 (Q2)	-0.38 / -0.36	-0.31	-16.13% (-0.05)
Apr 24, 2025	2025 (Q1)	-0.46 / -0.31	-0.36	13.89% (+0.05)
Feb 27, 2025	2024 (Q4)	-0.34 / -0.61	-0.45	-35.56% (-0.16)
Oct 30, 2024	2024 (Q3)	-0.33 / -0.28	-0.46	39.13% (+0.18)
Jul 25, 2024	2024 (Q2)	-0.40 / -0.31	-0.54	42.59% (+0.23)
May 02, 2024	2024 (Q1)	-0.42 / -0.36	-0.5	28.00% (+0.14)
Feb 22, 2024	2023 (Q4)	-0.52 / -0.45	-0.36	-25.00% (-0.09)
Oct 26, 2023	2023 (Q3)	-0.53 / -0.46	-0.25	-84.00% (-0.21)
Jul 27, 2023	2023 (Q2)	-0.50 / -0.54	-0.23	-134.78% (-0.31)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NVCR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	$16.51	$12.54	-24.05%
Apr 24, 2025	$17.77	$18.55	+4.39%
Feb 27, 2025	$21.96	$19.23	-12.43%
Oct 30, 2024	$16.89	$16.99	+0.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does NovoCure Ltd (NVCR) report earnings?

NovoCure Ltd (NVCR) is schdueled to report earning on Oct 23, 2025, TBA (Confirmed).

What is NovoCure Ltd (NVCR) earnings time?

NovoCure Ltd (NVCR) earnings time is at Oct 23, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NVCR EPS forecast?

NVCR EPS forecast for the fiscal quarter 2025 (Q3) is -0.42.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing